Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has obtained a GMP certificate for its new pre-filled formulation production lines from the European Medicines Agency, indicating compliance with EU standards. This certification is expected to enhance the company’s market competitiveness in Europe, where it already holds a strong position in the Enoxaparin Sodium formulations market, and support its internationalization strategy.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, specializing in the production of Enoxaparin Sodium prefilled injections. The company focuses on the global formulation business with a significant market presence in Europe and aims to support Chinese pharmaceutical enterprises in entering European and American markets.
YTD Price Performance: -2.02%
Average Trading Volume: 515,368
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$14.62B
See more insights into 9989 stock on TipRanks’ Stock Analysis page.